News | May 18, 2012

Novel Imaging for Sudden Cardiac Arrest Could Better Identify Patients Who Would Benefit From ICDs

May 18, 2012 - New research from the University at Buffalo suggests that cardiologists may have a new way to identify patients who are at the highest risk of sudden cardiac arrest, and the most likely to benefit from receiving an implantable cardiac defibrillator (ICD).

ICDs are used to prevent sudden cardiac arrest in patients with advanced heart disease, but many patients’ devices are never triggered. New research suggests that imaging the loss of nerve function in the heart may identify those patients at greatest risk of developing a life-threatening arrhythmia.

That finding was reported May 10 at 11 a.m. ET as a Late-Breaking Clinical Trial at the Heart Rhythm Society’s 33rd Annual Scientific Sessions in Boston.

The UB PAREPET study (Prediction of Arrhythmic Events with Positron Emission Tomography [PET]), is the largest PET imaging study ever done on sudden cardiac arrest.

UB researchers used PET imaging to quantify the patients’ amount of denervated myocardium, where sympathetic nerves in the heart have died or become damaged due to inadequate blood flow. This was accomplished by imaging the heart’s ability to take up a radioactive tracer of norepinephrine, the neurotransmitter released from the heart’s neurons, using the cyclotron-generated radiopharmaceutical 11C-hydroxyephedrine.

“The principal question we posed with this study was whether the amount of denervated myocardium could predict sudden cardiac arrest,” says James A. Fallavollita, M.D., UB professor of medicine and lead author on the study. “We found that when at least 38 percent of the heart was denervated, there was a significant increase in the risk of sudden cardiac arrest.”

“Ultimately, we wanted to develop an approach that could tackle the problem of identifying a larger portion of the patients with coronary artery disease who are at risk of developing sudden cardiac arrest,” explains John M. Canty Jr., M.D., the Albert and Elizabeth Rekate professor of medicine in the UB School of Medicine and Biomedical Sciences and UB's chief of cardiovascular medicine, who was principal investigator of the research. “Since many patients who suffer a cardiac arrest do not have severely depressed heart function, PET imaging may be able to identify high risk individuals who, in the future, could be considered candidates for an ICD.”

Currently, the main criteria for determining who gets an ICD is a measurement of heart function called the ejection fraction, which is the percentage of blood pumped by the heart with each beat. Individuals with an ejection fraction of 35 percent or less are considered candidates for ICDs because they have a significant risk of sudden cardiac arrest.

Funded by the National Institutes of Health, PAREPET involved 204 patients from western New York with advanced heart disease.

The current research study is a prime example of translational medicine because it came directly out of the laboratory research the UB researchers had performed in animals with chronic ischemic heart disease. These preclinical studies demonstrated that the risk of developing ventricular fibrillation was related to regional myocardial denervation.

“This is as clear an example of translational medicine as there is, with a project being taken from bench-to-bedside by the same investigative team,” says Canty. “In our preclinical research, we studied factors that lead to sudden cardiac arrest in animals. This led directly to the human study. This important finding may ultimately impact the care of patients with heart disease.”

This summer, Canty and Fallavollita will be among the core of UB translational medicine researchers who will move their laboratories into the university’s Clinical and Translational Research Center, in the top four floors of the new $291 million joint UB-Kaleida Health building now under construction on the Buffalo Niagara Medical Campus.

Other UB investigators participating in the PAREPET study included Michael E. Cain, M.D., vice president for health sciences and dean of the medical school, and Anne B. Curtis, Charles and Mary Bauer Professor and chair of the Department of Medicine, both international experts in cardiac electrophysiology; Sunil Baldwa, M.D., clinical assistant professor of medicine; Andrew J. Luisi, M.D., clinical assistant professor of medicine; Alan Hutson, chair and professor of the Department of Biostatistics in the School of Public Health and Health Professions; Terry Mashtare, Ph.D., research assistant professor in the same department; Suzanne Michalek, RN, clinical nurse specialist; and Brendan Heavy, MPH, research scientist in the Department of Medicine.

For more information: www.buffalo.edu/news/6903.

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
CZT SPECT camera detectors offered by GE.

A display of CZT SPECT gamma camera detectors at RSNA 2016. These detectors are more sensitive than those used in older cameras, allowing for faster scans or lower radiation dose. 

Feature | Nuclear Imaging| September 19, 2017 | Dave Fornell
Cardiac nuclear myocardial perfusion imaging (MPI) has been a mature area of imaging for years, but has recently star
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init